The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
New research involving ketamine continues show that having a mystical experience is key to the effectiveness of psychedelic ...
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...